undamentalytics Newsletter
Sign in

Assembly Biosciences, Inc. revenue

Assembly Biosciences, Inc.'s revenue was $72.3m in fiscal 2025, up 153.5% on the year before. Since fiscal 2017 ($9.0m) it has grown at a compound 29.7% a year. Over the last twelve months it was $74.8m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue09151679607297275
Growth on the year before——+64.1%+7.8%+395.6%−92.1%−100.0%—+298.2%+153.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Assembly Biosciences, Inc. $74.8m 125.1% -3.3%
Compugen LTD $72.8m 161.1% 302.6%
Viridian Therapeutics, Inc.\de $71.1m 23220.3% 264.4%
Wave Life Sciences, Inc. $70.9m 202.3% 20.7%
ADC Therapeutics SA $79.6m 3.0% —
Ascentage Pharma Group International $79.9m -41.4% —

Compare with peers

Head to head: ASMB vs CGENASMB vs VRDNASMB vs WVE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Assembly Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Assembly Biosciences, Inc.